Stockadora

8-K filings / November 20, 2026

Compass Therapeutics, Inc.: A stock exchange listing notice

Compass Therapeutics, Inc. filed a current report (Form 8-K) with the SEC on November 20, 2026. It reports a stock exchange listing notice.

AI-written from the facts below

In plain English

On November 19, 2026, the company received a notice from Nasdaq concerning its stock exchange listing. In the notice, Nasdaq states that the company does not meet a listing rule, specifically citing Nasdaq Listing Rule 5550(a)(2).

What each sentence states
“On November 19, 2026, the company received a notice from Nasdaq concerning its stock exchange listing.”
  • Item 3.01 of Form 8-K covers notices about a company's stock exchange listing.
  • Item 3.01: the exchange is Nasdaq.
  • Item 3.01: the company received the exchange's notice on November 19, 2026.
“In the notice, Nasdaq states that the company does not meet a listing rule, specifically citing Nasdaq Listing Rule 5550(a)(2).”
  • Item 3.01: the exchange is Nasdaq.
  • Item 3.01: what it reports: the exchange says the company does not meet a listing rule.
  • Item 3.01: the rule cited is Nasdaq Listing Rule 5550(a)(2).
  • Item 3.01: the company received the exchange's notice on November 19, 2026.
Written by an AI model from the facts on this page only; code and a second model checked every sentence against them.

Item 3.01

Stock exchange listing notice

  • Exchange Nasdaq From the filing
    Source
    “On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
  • What it says The company does not meet a listing rule From the filing
    Source
    “On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
  • Rule cited Nasdaq Listing Rule 5550(a)(2) From the filing
    Source
    “On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
  • Notice date November 19, 2026 From the filing
    Source
    “On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov

Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.